Company / R&D Expense
West Pharmaceutical Services R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$74.3M
FY2025
5-year range
$38.9M / $74.3M
FY2021-FY2025
Trend
+7.5%
vs FY2024
Sector context
#68 of 110
Health Care
What the data says
At $74M, West Pharmaceutical Services's r&d expense ranks #68 of 110 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $39M in FY2021 to $74M in FY2025.
Based on SEC 10-K filings.
$74M in FY2025 with a 5-year CAGR of +13.0%.
Improved from $68M to $74M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +16.6%
- 5-Year CAGR
- +13.0%
- 10-Year CAGR
- -
Sector benchmark
#68 of 110 in Health CareTop 62% of 110This company $74.3M Sector average $298.2M
▼
-75.1% below sector average
Key checks
Key Insights
- West Pharmaceutical Services's r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +13.0%, indicating consistent growth.
- In FY2025, r&d expense increased 7.5% year-over-year.
- Ranks #68 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.3M | +7.5% |
| FY2024 | $69.1M | +1.0% |
| FY2023 | $68.4M | +45.8% |
| FY2022 | $46.9M | +20.6% |
| FY2021 | $38.9M | -3.5% |
| FY2020 | $40.3M | +3.6% |
| FY2019 | $38.9M | -3.5% |
| FY2018 | $40.3M | +3.1% |
| FY2017 | $39.1M | +4.8% |
| FY2016 | $37.3M | -1.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026